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Background: Pericardiotomy for cancer patients with effusion can alleviate symptoms, but
with unclear effect on long term survival. Our experience with VATS technique has pro-
duced some long-term survivors.
Methods: A retrospective review of 62 VATS pericardiotomy for pericardial effusion in pa-
tients with known malignancy. Kaplan–Meier survival curves and Log-Rank tests were
used for analysis.
Results: The mean age was 54.8  14.3 years (ranging from 19 to 79). The mean hospital stay
was 8.7  5.5 days. The median survival was 6.75 months (range 1 month–10 years). Overall
one-year survival was 44.2%, 3-year survival 17.6%, and 5-year survival 10% after drainage
of pericardial effusion. The mean survival in cytology negative patients (n ¼ 21) was
13.4  0.98 months, compared to 4.89 0.9 months in cytology positive patients (n ¼ 27)
( p ¼ 0.0175). The 5-year survival in cytology negative patients was 19.6%, while none of the pa-
tients with positive cytology were alive after 36 months. The mean survival in patients with no
evidence of metastatic disease on the pericardium (n ¼ 28) was 12.8  0.9 months, compared
to patients with metastatic disease of the pericardium (n ¼ 22) 4.66  0.8 months ( p ¼ 0.026).
Conclusions: VATS Pericardiotomy can provide effective long-term drainage in patients with
symptomatic pericardial effusion. Positive cytology and metastatic involvement of the
pericardium are predictive of worse survival. Survival greater than 5 years can be expected
in 19% and 17% of patients with negative fluid cytology and negative metastatic disease of
the pericardium, respectively.
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invasive video-assisted thoracoscopic surgery (VATS) pericar-
diotomy (pericardial window).1–4
Previous studies have reported a poor prognosis for cancer
patients with symptomatic pericardial effusions, with median
survivals of 3 months or less.5–8 The mean survival depends
upon the extent of disease and tumor type.1–4 Although
multiple methods of operative and non-operative drainage
of pericardial effusions have been described, surgical pericar-
dial window has the lowest reported recurrence rate ranging
from 8% to 10%.9 Pericardiocentesis alone for patients with
a history of cancer has a recurrence rate of 90% over
a 3 months period.1,10
Surgical approaches in the past included median sternot-
omy or anterolateral thoracotomy with their attendant mor-
bidity. A thoracoscopic pericardial window has been shown
to be an effective and safe procedure in management of
the life-threatening hemodynamic effects of cardiac tampo-
nade.11–14 Thoracoscopy allows an excellent view of both the
pleural cavity and pericardium and the precise selection of
pericardiotomy sites.14,15 We note that patients with negative
cytology and negative pathological examination of the peri-
cardium have the greatest likelihood of long term survival.2. Methods
Sixty-two patients with a history of malignancy who under-
went VATS pericardiectomy for symptomatic pericardial effu-
sion between 1999 and 2004 were retrospectively analyzed.
Fluid cytology as well as metastatic involvement of the peri-
cardium, seen within the pathologic specimen, were used as
independent variables to dichotomize the cohort into those
with cytology-positive effusions and those with cytology-
negative effusions, as well as with or without metastatic
disease of the pericardium. Kaplan–Meier survival curves
and Log-Rank List were used to analyze the data.
2.1. Surgical technique
The operative side was often chosen based upon associated
pleural effusions in anticipation of ipsilateral pleurodesis.
After induction of general anesthesia, a 10 mm port was
placed in the fourth or fifth intercostal space (ICS) in the
mid-axillary line. A second port was placed in the 6th ICS be-
tween the mid- or posterior-axillary lines. If a third port was
needed, it was placed in the 7th ICS in the anterior-axillary
line. The camera was introduced through one of the two pos-
terior ports and the pleural space and surface of the pericar-
dium were inspected. In instances where the pericardium
was markedly distended with fluid, it was often aspirated
with a needle. Decompression of the pericardium allowed
for easier grasping and manipulation of the pericardium.
The pericardium was grasped with an Allis clamp placed
through the anterior port, and was incised with either an elec-
trocautery hook or thoracoscopic scissors placed through one
of the posterior ports. After the initial incision in the pericar-
dium, the heart was inspected underneath in order to insure
that it was away from the cautery and sharp instruments. A
window was created approximately 3 cm in diameter. Witha right sided approach, the window was created anterior to
the phrenic nerve, while with the left sided approach, the win-
dow was placed anteriorly, posteriorly, or in both locations
(Fig. 1). A pericardial drain was placed via the window in a de-
pendant fashion and a second drain was left in the pleural
space. Intraoperative talc pleurodesis was performed in the
presence of a moderate or large pleural effusion. Each drain
was removed when the drainage was equal or less than
100–200cc/24 h, usually after 48 h.3. Results
Sixty-two patients met criteria of having a symptomatic peri-
cardial effusion requiring intervention and a history of malig-
nancy. The study was approved by the Institutional Review
Board at Brigham and Women’s Hospital/Dana Farber Insti-
tute. There were 34 men (54.8%) and 28 women (45%). The
mean age was 54.8  14.3 years (ranging from 19 to 79). The
most common histology of the primary malignancy was either
small cell or non-small cell lung cancer (32/62, 51.6%). Other
histologies included breast adenocarcinoma (n ¼ 8; 12.9%),
esophageal adenocarcinoma (n ¼ 5; 8%) non-Hodgkin’s lym-
phomas (n ¼ 5; 8%), leukemia (n ¼ 3; 4.8%) and 10 other cases
(16%) listed in Table 1. There were no perioperative deaths
within 30 days of the operative procedure. Ventilation support
was required beyond the day of surgery in 1 patient, who was
extubated 48 h after surgery. Mean hospital stay was
8.7  5.5 days.
Overall median survival was 6.76 months, (range 1 month–
10 years). For the entire group, one-year survival was 44.2%,
three-year survival was 17.6%, and five-year survival was
10% (Fig. 2). Mean survival for female patients was
11.6 months, compared to 4.8 months for men; this did not
reach statistical significance in this small cohort. There was
no difference in survival when patients were dichotomized
for age at 65 years ( p ¼ 0.4).
Pericardial fluid and the pericardium were examined for
cytologic and pathologic evidence of malignant cells, respec-
tively. The cytologic evaluation of pericardial fluid was per-
formed in 48 of 62 patients (77.4%) and histologic evaluation
of metastatic disease of the pericardium in 50 of 62 patients
(80.6%). The mean survival in cytology negative patients
(n ¼ 21) was 13.4  0.98 months, compared to cytology positive
patients (n ¼ 27) 4.89  0.9 months ( p ¼ 0.0175) (Fig. 3). The
5-year survival in cytology negative patients was 19.6%, while
none of the patients with metatstatic disease of the pericar-
dium were alive after 36 months. The mean survival in pa-
tients with malignant disease of the pericardium (n ¼ 28)
was 4.66  0.8 months, compared to 12.8  0.9 months in
patients with no malignant disease of the pericardium
(n ¼ 22) ( p ¼ 0.026). Fig. 4 demonstrates the difference in
survival based on metastatic involvement of the pericardium.
We compared mean survival of patients with lung and
esophageal cancer (LE; n ¼ 37) with all other types of cancer
(Oth; n ¼ 25). The median survival of patients for LE group
was 4.8 months and for Oth group was 13.4 months,
p ¼ 0.064 (statistically not significant). The one-year survival
in the LE group was 28%, while it was 57% in the Oth group.
The 2-year survival was 17.8% in the LE group, and 32% in
Fig. 1 – Schematic illustration of operative approach. A. A nerve hook can be used to facilitate the initial incision into the
distended pericardium. B. Release of fluid from the pericardium. C. A large window anterior (to phrenic nerve). D. Anterior
and posterior pericardial windows and their relation to phrenic nerve.22
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was 16.2%, while none of the patients in the LE group was alive
after 46 months (Fig. 5).
The majority of patients had only anterior pericardiectomy
(n ¼ 48; 77.4%), 3 patients had posterior pericardiectomy only,
and 11 patients had combined anterior and posterior pericar-
diectomy. Seven patients (11%) needed a repeat pericardial
window at a later time. Recurrent symptomatic effusion de-
veloped in 4 cases (6.45%) after an anterior pericardial window
only, in 2 cases after posterior pericardial window only, and in
1 case after a combined anterior and posterior PW. The last
case had a window placed from a left-sided approach, and sub-
sequently developed a loculated symptomatic effusion on the
right, which was drained with a right approach VATS and cre-
ation of a new pericardial window. There was no statistically
significant correlation between the site of pericardicetomyTable 1 – The underlying pathology
Pathology of malignant
pericardial effusion
n
NSCLC & SCLC 32
Breast cancer 8
Esophageal neoplasm 5
Non-Hodgkin-lymphoma 5
Leukemia 3
Other tumors and metastatic disease* 10
* Thymoma 1, malignant melanoma 1, osteosarcoma 1, rhabdo-
myosarcoma 1, nerve sheath tumor 1, colon ca 2, ovarian ca 1,
testicular ca 1, squamous cell cancer of unknown origin 1.and the recurrence rate. Concomitant pleurodesis was per-
formed in 15 (24.2%) patients. The mean hospital stay was
8.7  5.5 days. There was no correlation between length of hos-
pital stay and long-termsurvival, nor between age and survival.4. Discussion
Video-assisted thoracic surgery (VATS) pericardial window
was safely and effectively applied to our cancer patient popu-
lation with no perioperative deaths from the procedure. Fur-
thermore, 43% of all patients survived over a year, despite
the poor prognosis predicted from the previous literature.
More importantly, we found that pericardial cytology0.0
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Fig. 2 – Overall mean survival of patients.
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Fig. 3 – Comparing the mean survival in patients with
positive and negative cytology.
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Fig. 5 – Comparing the mean survival in patients with lung
and esophagus vs patients with all other malignancies
combined.
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tive cytology living two years and 19% living 5 years, whereas
no patients with positive cytology lived beyond 36 months.
Metastatic involvement of the pericardium is another strong
predictor of survival in this patient population, with 17% of
patients with negative pericardial involvement living 5 years
or longer, while none of the patients with metastatic disease
of the pericardium were alive beyond 36 months. Cytologic
analysis and evaluation of metastatic disease were performed
in 48 (77.4%) and 50 (80.6%) patients, respectively.
Age had no influence on survival, nor did the site of the
primary malignancy. This is likely due to the impact of the ad-
vanced malignancy on survival in all these patients, blunting
the effect of these lesser influences.
The observation that a VATS pericardial window is safe
and effective is supported by previous authors.11,12 Mack
et al.11,12 previously reported that VATS for extensive pericar-
dial resection was equivalent to open thoracotomy, but with
morbidity less than or equal to a subxiphoid pericardial win-
dow.12 Reitknecht et al.8 published a series of 66 patients
with malignant pericardial effusion treated by VATS pericar-
dial window with no deaths or major complications attributed
to the procedure. O’Brien et al.9 compared the efficacy of 15
VATS pericardial windows with 71 subxiphoid approaches.0.0
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Fig. 4 – Comparing the mean survival in patients with
positive and negative metastatic disease of pericardium
cytology.They found no in-hospital mortality after the VATS procedure,
compared to a 13% mortality following the subxiphoid proce-
dure (perhaps due to moribund patients being offered subxi-
phoid technique with local anesthesia). Recurrence was
observed in 1 patient after VATS (8%) and in 5 patients after
subxiphoid approach (10%), similar to our recurrence rate.
Other authors have disagreed with our findings. In a series
by Piehler et al., fifteen patients (10.3%) had late constriction
or recurrent effusion. Six of these required re-operation.16
O’Brien found a longer anesthesia time with the VATS proce-
dure compared to the subxiphoid approach, and a slightly
higher procedural morbidity (2.7% vs. 2%).9 De la Gandara
et al.17 published a series of 13 patients with malignant peri-
cardial effusion and tamponade. The mean survival in their
small series was only 4 months. Anderson et al.18 reported
a median survival of 6 months after VATS pericardial window
in a series of 59 cancer patients with malignant pericardial ef-
fusion. Cullinane et al.19 reported in a series of 63 patients that
survival correlates with type of malignancy (worse for NSCLC),
concomitant presence of a pleural effusion, and positive path-
ologic or cytologic findings. Our data are in accordance with
Cullinane’s finding. Reitknecht et al. also reported that one-
year survival following VATS pericardiotomy was only 26%
with 50% of patients dead within 3 months of operation.
They suggested that poor prognosis of the disease led to
poor survival rates, but should not preclude palliating symp-
toms in this population.8 We believe the primary driver of
long-term survival is the tumor burden and biologic behavior
within the patient population, and this likely explains the
differences in survival rates between the author groups.
Although we are encouraged by our long-term results, we
acknowledge that our analysis is retrospective and non-ran-
domized. Also, the procedures were performed by a large
group of thoracic surgeons, with different biases and slightly
different techniques, thus limiting the uniformity of the pro-
cedure. Finally, in order to obtain enough data to analyze,
we grouped together patients with the same operative inter-
vention but with a heterogeneous group of malignancies
with different biologic behaviors. These factors influence the
power of our conclusions in terms of long-term results.
This cohort highlights a simple observation that a symp-
tomatic pericardial effusion in a patient with a history of
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a benign effusion. Few of the previous authors evaluated the ef-
fect of positive cytology on survival. In our series, patients with
positive cytology had a survival similar to the experience of the
previous authors with a mean survival of 4.7 months. Patients
with a negative cytology had a much better survival with 43%
surviving over a year, and 19% living 5 years or more. In Piehler
et al’s series17 the one year survival was 23% overall, but 85.6%
for patients with idiopathic effusions after VATS pericardiot-
omy.Olsenetal.20 performedapericardialwindowusingasmall
left anterior thoracotomy in 28 patients. In only 47% of patients,
the etiology was malignant disease. The 5-year survival rate in
patients with non-malignant effusions was 60%, while the
2-year survival in patients with malignant effusions was only
20%.20 Benign causes of pericardial effusions in patients with
malignancy include impaired immune system, impaired renal
function, hypoalbuminemia, and impaired cardiac function.
Farsak et al.21 conducted a prospective study in 150
patients with pericardial effusion. Half of the patients were
treated with a pericardiectomy posterior to the phrenic nerve
on the left side. The control group received conventional treat-
ment only. A posterior pericardiotomy reduced the prevalence
of early pericardial effusion, atrial fibrillation, and late pericar-
dial effusion with tamponade.21 In our series, a good number
of patients (n ¼ 11, 17%) had combined anterior and posterior
pericardial window, which might explain the low recurrence
rate in our series.5. Conclusion
Video-assisted thoracoscopic pericardial window is an effec-
tive technique for pericardial drainage and can provide long
term relief of bothersome symptoms. While our results com-
pare favorably with the historic data in current literature,
they also indicate that the short survival of patients is not
a contra-indication for VATS pericardial window, and selected
patients may achieve significant improvement in palliation
and long-term survival with prompt recognition and appropri-
ate intervention. The positive cytology of pericardial fluid and
metastatic involvement of the pericardium are strong predic-
tors of survival in this patient population.
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